Publication
Article
Supplements and Featured Publications
Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 StudyVolume
Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
This publication was sponsored by Debiopharm International SA.
This Clinical Brief explores the double-blind, multicentre, randomised phase 2 study (NCT02022098) of Debio 1143 and high-dose cisplatin chemoradiotherapy in patients with high-risk locoregionally advanced squamous cell carcinoma of the head and neck.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
